---
title: "Zhendong Pharmacy: Vaginal Lactobacillus Dual Live Bacteria Capsules Achieve Primary Research Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250779642.md"
description: "Zhendong Pharmacy announced that its investee company Longchuang Biopharmaceutical's research project on vaginal Lactobacillus dual live bacteria capsules has reached the primary endpoint of the Phase III clinical trial. This capsule is used for the treatment of bacterial vaginosis caused by dysbiosis, employing an innovative mechanism of \"using bacteria to treat bacteria,\" which has differentiated advantages. The company will recently submit a communication application prior to the marketing authorization application to the National Medical Products Administration's Drug Evaluation Center, actively promoting the marketing process of this capsule"
datetime: "2025-07-30T11:45:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250779642.md)
  - [en](https://longbridge.com/en/news/250779642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250779642.md)
generator: "portal-rs"
---

# Zhendong Pharmacy: Vaginal Lactobacillus Dual Live Bacteria Capsules Achieve Primary Research Endpoint

Zhendong Pharmacy announced that its investee company Longchuang Pharmaceutical's research project on vaginal Lactobacillus dual live bacteria capsules has reached the primary endpoint in the Phase III clinical trial. This capsule is used for the treatment of bacterial vaginosis caused by dysbiosis, employing an innovative mechanism of "treating bacteria with bacteria," which has differentiated advantages. The company will recently submit a communication application prior to the marketing authorization application to the National Medical Products Administration's Drug Evaluation Center, actively promoting the marketing process of this capsule

### Related Stocks

- [300158.CN](https://longbridge.com/en/quote/300158.CN.md)

## Related News & Research

- [CLSA: US Treasury Interest Expenses Surge, Emerging Market Fund Flows Shift to Taiwan, S Korea and India](https://longbridge.com/en/news/296582942.md)
- [M Stanley: XIAOMI-W  2Q Smartphone Margin Surprise, Expects Resilience in 2H](https://longbridge.com/en/news/296303100.md)
- [Investcorp Acquires 20Cube 3Pl Solutions](https://longbridge.com/en/news/296313505.md)
- [CoTec-backed MagIron reports strong results from independent DR-grade iron pellet tests](https://longbridge.com/en/news/296478902.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**